ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga

[cafead]

via Roche has shared phase 3 data on the drug that enhanced the efficacy of Johnson & Johnson’s Zytiga in a subset of prostate cancer patients earlier this year. The trial squeezed under the bar for statistical significance by improving on the median progression-free survival (PFS) of Zytiga by two months.

article source